Physician profile
Derrick D Eichele
NPI 1023304607
$53,551.35
in general payments reported to CMS, 2019-2025
28 companies · $6,601 in 2025
The $6,601 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.02 · 2022: $9,966 · 2023: $12K · 2024: $25K · 2025: $6,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $5,588 · Consulting Fee: $2,300 · Travel and Lodging: $237 · Education: $73.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,325.00 |
| Food and Beverage | $5,588.46 |
| Consulting Fee | $2,300.00 |
| Travel and Lodging | $236.99 |
| Education | $73.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,490.43 | 2021-2025 | |
| Pfizer INC. | $10,078.98 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $9,123.61 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $663.36 | 2024-2025 | Zenpep |
| Janssen Biotech, INC. | $659.70 | 2023-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $348.79 | 2023-2025 | |
| Madrigal Pharmaceuticals | $306.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $264.94 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.37 | 2023-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $195.59 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $169.12 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $133.68 | 2024-2025 | Entyvio, Eohilia |
| Ipsen Biopharmaceuticals, INC | $127.35 | 2023-2025 | Iqirvo, Bylvay |
| Celgene Corporation | $117.24 | 2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $114.94 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Steris Corporation | $101.16 | 2022 | |
| Olympus America INC. | $94.82 | 2023 | Evis Exera III Video System Center |
| Ironwood Pharmaceuticals, INC | $86.38 | 2024 | |
| Janssen Scientific Affairs, LLC | $65.86 | 2024 | Stelara |
| Ardelyx, INC. | $58.85 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $32.38 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $24.63 | 2024 | Sucraid |
| Alnylam Pharmaceuticals INC. | $21.25 | 2025 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.03 | 2024 | Cyltezo |
| Merck Sharp & Dohme LLC | $16.86 | 2023 | Dificid |
| Ferring Pharmaceuticals INC. | $15.73 | 2025 | Rebyota |
| Organon LLC | $14.23 | 2024 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Eichele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.